175 related articles for article (PubMed ID: 7553886)
1. B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma.
Yeh KY; Pulaski BA; Woods ML; McAdam AJ; Gaspari AA; Frelinger JG; Lord EM
Cell Immunol; 1995 Oct; 165(2):217-24. PubMed ID: 7553886
[TBL] [Abstract][Full Text] [Related]
2. Expression of B7-1 by Pam 212 squamous cell carcinoma enhances tumor cell interactions with dendritic epidermal cells but does not affect in vivo tumor growth.
Yeh KY; Chen Z; Nasir A; Ohsuga Y; Takashima A; Lord EM; Gaspari AA
J Invest Dermatol; 1997 Dec; 109(6):728-33. PubMed ID: 9406812
[TBL] [Abstract][Full Text] [Related]
3. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization.
Gajewski TF; Fallarino F; Uyttenhove C; Boon T
J Immunol; 1996 Apr; 156(8):2909-17. PubMed ID: 8609411
[TBL] [Abstract][Full Text] [Related]
4. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules.
Yang G; Hellström KE; Hellström I; Chen L
J Immunol; 1995 Mar; 154(6):2794-800. PubMed ID: 7533183
[TBL] [Abstract][Full Text] [Related]
5. Costimulatory molecules are active in the human xenoreactive T-cell response but not in natural killer-mediated cytotoxicity.
Tadaki DK; Craighead N; Saini A; Celniker A; Burkly LC; Lee KP; Chute JP; Harlan DM; Kirk AD
Transplantation; 2000 Jul; 70(1):162-7. PubMed ID: 10919595
[TBL] [Abstract][Full Text] [Related]
6. The role of the CD28/B7 interaction in the regulation of NK cell responses during infection with Toxoplasma gondii.
Hunter CA; Ellis-Neyer L; Gabriel KE; Kennedy MK; Grabstein KH; Linsley PS; Remington JS
J Immunol; 1997 Mar; 158(5):2285-93. PubMed ID: 9036976
[TBL] [Abstract][Full Text] [Related]
7. Triggering of murine NK cells by CD40 and CD86 (B7-2).
Martín-Fontecha A; Assarsson E; Carbone E; Kärre K; Ljunggren HG
J Immunol; 1999 May; 162(10):5910-6. PubMed ID: 10229827
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors.
Zitvogel L; Robbins PD; Storkus WJ; Clarke MR; Maeurer MJ; Campbell RL; Davis CG; Tahara H; Schreiber RD; Lotze MT
Eur J Immunol; 1996 Jun; 26(6):1335-41. PubMed ID: 8647214
[TBL] [Abstract][Full Text] [Related]
9. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro.
Gajewski TF
J Immunol; 1996 Jan; 156(2):465-72. PubMed ID: 8543795
[TBL] [Abstract][Full Text] [Related]
10. B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors.
Greenfield EA; Howard E; Paradis T; Nguyen K; Benazzo F; McLean P; Höllsberg P; Davis G; Hafler DA; Sharpe AH; Freeman GJ; Kuchroo VK
J Immunol; 1997 Mar; 158(5):2025-34. PubMed ID: 9036945
[TBL] [Abstract][Full Text] [Related]
11. CD28 ligation by monoclonal antibodies or B7/BB1 provides an accessory signal for the cyclosporin A-resistant generation of cytotoxic T cell activity.
Van Gool SW; de Boer M; Ceuppens JL
J Immunol; 1993 Apr; 150(8 Pt 1):3254-63. PubMed ID: 7682237
[TBL] [Abstract][Full Text] [Related]
12. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
Li Y; McGowan P; Hellström I; Hellström KE; Chen L
J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
[TBL] [Abstract][Full Text] [Related]
13. T cells of staphylococcal enterotoxin B-tolerized autoimmune MRL-lpr/lpr mice require co-stimulation through the B7-CD28/CTLA-4 pathway for activation and can be reanergized in vivo by stimulation of the T cell receptor in the absence of this co-stimulatory signal.
Zhou T; Weaver C; Linsley PS; Mountz JD
Eur J Immunol; 1994 May; 24(5):1019-25. PubMed ID: 7514125
[TBL] [Abstract][Full Text] [Related]
14. B7.1 expression eliminates tumor resistance to IL-12 gene therapy.
Heise CP; Shi F; Albertini MR; Mahvi DM
Cancer Gene Ther; 2001 Feb; 8(2):118-27. PubMed ID: 11263527
[TBL] [Abstract][Full Text] [Related]
15. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
[TBL] [Abstract][Full Text] [Related]
16. NK cell triggering by the human costimulatory molecules CD80 and CD86.
Wilson JL; Charo J; Martín-Fontecha A; Dellabona P; Casorati G; Chambers BJ; Kiessling R; Bejarano MT; Ljunggren HG
J Immunol; 1999 Oct; 163(8):4207-12. PubMed ID: 10510357
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors.
Martin-Fontecha A; Cavallo F; Bellone M; Heltai S; Iezzi G; Tornaghi P; Nabavi N; Forni G; Dellabona P; Casorati G
Eur J Immunol; 1996 Aug; 26(8):1851-9. PubMed ID: 8765031
[TBL] [Abstract][Full Text] [Related]
18. Intrinsic and extrinsic manipulation of B7/CTLA-4 interaction for induction of anti-tumor immunity against osteosarcoma cells.
Nagamori M; Kawaguchi S; Murakami M; Wada T; Nagoya S; Yamashita T; Inobe M; Uede T
Anticancer Res; 2002; 22(6A):3223-7. PubMed ID: 12530068
[TBL] [Abstract][Full Text] [Related]
19. Activation of CD4+ T cells by delivery of the B7 costimulatory signal on bystander antigen-presenting cells (trans-costimulation).
Ding L; Shevach EM
Eur J Immunol; 1994 Apr; 24(4):859-66. PubMed ID: 7512033
[TBL] [Abstract][Full Text] [Related]
20. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Sharpe AH; Vallera DA
J Immunol; 1999 Jun; 162(11):6368-77. PubMed ID: 10352249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
